Molecular diagnostic tools are driving innovation and investment, shaping a core business area in biotech, pharma and device companies. The shift toward developing diagnostic platforms comes from the advances in sequencing, microarrays, and microfluidics. The availability of new sequencing platforms and point-of-care assays will stimulate the growth in the field by providing greater speed, convenience and sensitivity, leading to improved outcomes and greater cost savings.

Tracks
11-12 October
Molecular Diagnostics for Cancer
Convergence of Technologies for Point-of-Care Diagnostics
12-13 October
Molecular Diagnostics for Infectious Disease
 
NGS: Molecular Diagnostics Magnified

 

Cambridge Healthtech Institute  |  250 First Avenue, Suite 300  |  Needham MA 02494  |   phone: 781-972-5400  |   fax: 781-972-5425 chi@healthtech.com